Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK's Avodart To Get Panel Review For Prostate Cancer Prevention, With Merck's Proscar Along For The Ride

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Oncology Drugs Advisory Committee will review Merck's Proscar (finasteride) as well as GlaxoSmithKline's Avodart (dutasteride), even though Merck has not filed an sNDA.

You may also be interested in...



Prostate Cancer Risk Reduction sNDAs Go Before ODAC, Pitting Statistical Versus Clinical Significance

GlaxoSmithKline's Avodart and Merck's Proscar reduce the risk of low-grade prostate cancers in trials, but FDA's Oncologic Drugs Advisory Committee will hear the agency argue on Dec. 1 that the actual benefit of this is questionable.

Prostate Cancer Risk Reduction sNDAs Go Before ODAC, Pitting Statistical Versus Clinical Significance

GlaxoSmithKline's Avodart and Merck's Proscar reduce the risk of low-grade prostate cancers in trials, but FDA's Oncologic Drugs Advisory Committee will hear the agency argue on Dec. 1 that the actual benefit of this is questionable.

Reeling From Ferrlecit Loss, Watson Revamps Branded Sales Strategy

Insurance coverage was an "obstacle to launch," for Rapaflo and Gelnique, but the outlook is much better for 2010, says Watson.

Related Content

Topics

UsernamePublicRestriction

Register

PS071353

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel